{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:47:30Z","timestamp":1790347650778,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007459","name":"Multiple Sclerosis International Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106878","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:30:43Z","timestamp":1764030643000},"page":"106878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings"],"prefix":"10.1016","volume":"105","author":[{"given":"Nick","family":"Rijke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem I","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Saylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Piggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Laurson-Doube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas K","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia Del","family":"Giovane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najoua El","family":"Abkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-2347","authenticated-orcid":false,"given":"Anne","family":"Helme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Prato Chichiraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ali Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106878_bib0045","unstructured":"A.10 Cladribine, glatiramer and rituximab - multiple sclerosis - EML [Internet] [cited 2023 Sep 15]. Available from: https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/24th-eml-expert-committee\/a10_ms-dmts."},{"key":"10.1016\/j.msard.2025.106878_bib0014","article-title":"Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland","volume":"40","author":"Airas","year":"2020","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"10.1016\/j.msard.2025.106878_bib0032","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106878_bib0033","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0041","article-title":"No early effect of intrathecal Rituximab in progressive multiple sclerosis (EFFRITE Clinical Trial)","volume":"2021","author":"Bonnan","year":"2021","journal-title":"Mult Scler Int"},{"issue":"6","key":"10.1016\/j.msard.2025.106878_bib0016","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing\u2013remitting multiple sclerosis","volume":"268","author":"Boremalm","year":"2021","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.msard.2025.106878_bib0024","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","article-title":"BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis","volume":"50","author":"Bukhari","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.msard.2025.106878_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of Rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106878_bib0036","unstructured":"Crescenzo F.D., Amato L., Vecchi S., Mitrova Z., Cruciani F., Saulle R., et al. Acceptability, equity, feasibility, and values of rituximab and azathioprine for the treatment of multiple sclerosis: a rapid systematic review protocol. 2021 Mar 24 [cited 2024 Aug 1]; Available from: https:\/\/osf.io\/w9gs8\/."},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/pn-2022-003426","article-title":"Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines","volume":"23","author":"Dobson","year":"2023","journal-title":"Pract Neurol"},{"key":"10.1016\/j.msard.2025.106878_bib0027","unstructured":"Drugs@FDA: FDA approved Drug products [Internet] [cited 2018 Nov 27]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"issue":"11","key":"10.1016\/j.msard.2025.106878_bib0035","article-title":"Rituximab for people with multiple sclerosis","volume":"11","author":"Filippini","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.msard.2025.106878_bib0002","first-page":"269","article-title":"Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2025.106878_bib0010","unstructured":"Health M of. Limited Coverage Drugs \u2013rituximab - Province of British Columbia [Internet]. Province of British Columbia; [cited 2024 Dec 6]. Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/programs\/limited-coverage-drug-program\/limited-coverage-drugs-rituximab."},{"issue":"4","key":"10.1016\/j.msard.2025.106878_bib0028","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.msard.2025.106878_bib0013","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.26352","article-title":"Group for the KPSCMS specialist. Decreasing multiple sclerosis treatment expenditures and improving quality at the health system level","volume":"92","author":"Langer-Gould","year":"2022","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.msard.2025.106878_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1016\/j.msard.2025.106878_bib0039","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106878_bib0015","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106878_bib0025","unstructured":"MabThera | European Medicines Agency (EMA) [Internet]. 2009 [cited 2024 Aug 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera."},{"issue":"7","key":"10.1016\/j.msard.2025.106878_bib0042","first-page":"857","article-title":"Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value: a summary from the Institute for Clinical and Economic Review\u2019s New England Comparative Effectiveness Public Advisory Council","volume":"29","author":"McKenna","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.msard.2025.106878_bib0019","article-title":"Treatment outcomes in multiple sclerosis using reduced and extended interval ocrelizumab dosing","volume":"102","author":"McLean","year":"2025","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"10.1016\/j.msard.2025.106878_bib0020","article-title":"Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: a systematic review and meta-analysis","volume":"103","author":"Mohammadi","year":"2025","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"10.1016\/j.msard.2025.106878_bib47","unstructured":"MOLT Panel. Should rituximab vs. no disease-modifying therapy be used for relapsing forms of multiple sclerosis when switching from another DMT? [cited 2025 Feb 12]. Should rituximab vs. no disease-modifying therapy be used for relapsing forms of multiple sclerosis when switching from another DMT? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_14a989f7-1814-4ff9-ad82-743ece0d1399\/4fb6702c-0347-4665-835a-42f9e5d5a1a5."},{"key":"10.1016\/j.msard.2025.106878_bib49","unstructured":"MOLT Panel. Should rituximab vs. other disease-modifying therapies be used for relapsing forms of multiple sclerosis when switching from another DMT? [cited 2025 Feb 12]. Should rituximab vs. other disease-modifying therapies be used for relapsing forms of multiple sclerosis when switching from another DMT? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_f7ffe858-2eb5-40da-8966-1bac958b5287\/1ad0f326-37b6-42e1-b2bf-4f72a7f350fa."},{"key":"10.1016\/j.msard.2025.106878_bib50","unstructured":"MOLT Panel. Should rituximab vs. no disease-modifying therapy be used for treatment-na\u00efve progressive forms of multiple sclerosis? [cited 2025 Feb 12]. Should rituximab vs. no disease-modifying therapy be used for treatment-na\u00efve progressive forms of multiple sclerosis? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_9ab56f6d-b2a5-4d7e-961c-cac920a7bcc5\/d4a56787-b518-4e96-b810-800a9c3cf022."},{"key":"10.1016\/j.msard.2025.106878_bib51","unstructured":"MOLT Panel. Should rituximab vs. other disease-modifying therapies be used for treatment-na\u00efve progressive forms of multiple sclerosis? [cited 2025 Feb 12]. Should rituximab vs. other disease-modifying therapies be used for treatment-na\u00efve progressive forms of multiple sclerosis? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_1486eaf0-a0e4-412f-9183-5e4e1e8c7ab0\/d9a904d9-d7da-4a6d-a354-49fb58e4daa2."},{"key":"10.1016\/j.msard.2025.106878_bib52","unstructured":"MOLT Panel. Should rituximab vs. no disease-modifying therapy be used for progressive forms of multiple sclerosis when switching from another DMT? [cited 2025 Feb 12]. Should rituximab vs. no disease-modifying therapy be used for progressive forms of multiple sclerosis when switching from another DMT? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_ae7d3031-43ea-4deb-8a18-bf865d2fc953\/1a614577-8747-4a2b-8a92-c8ff47fe0c56."},{"key":"10.1016\/j.msard.2025.106878_bib53","unstructured":"MOLT Panel. Should rituximab vs. other disease-modifying therapies be used for progressive forms of multiple sclerosis when switching from another DMT? [cited 2025 Feb 12]. Should rituximab vs. other disease-modifying therapies be used for progressive forms of multiple sclerosis when switching from another DMT? Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_1984d196-ab5b-43a3-835e-9ded5c73c8cd\/e725fad4-5094-49ce-bcdd-b19a9e2bd910."},{"key":"10.1016\/j.msard.2025.106878_bib0006","unstructured":"MS International Federation [Internet] [cited 2024 Aug 2].. Atlas of MS 2020 - clinical management report. Available from: https:\/\/www.msif.org\/resource\/atlas-of-ms-2020-clinical-management-report\/."},{"key":"10.1016\/j.msard.2025.106878_bib0003","unstructured":"MSIF. Atlas of MS [Internet] [cited 2024 Mar 8]. Available from: https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms."},{"key":"10.1016\/j.msard.2025.106878_bib0009","unstructured":"Norwegian Institute of Public Health [Internet]. 2018 [cited 2024 Aug 1]. Health Technology assessment of medicines used for multiple sclerosis. Available from: https:\/\/www.fhi.no\/en\/projects\/Health-Technology-Assessment-of-medicines-used-for-multiple-sclerosis\/."},{"key":"10.1016\/j.msard.2025.106878_bib0043","unstructured":"M.O.L.T. Panel. Should rituximab vs. other disease-modifying therapies be used for treatment-na\u00efve relapsing forms of multiple sclerosis? [Internet] [cited 2024 Sep 12].. Available from: https:\/\/guidelines.gradepro.org\/preview\/p_l_justyna_litynska_admin_evidenceprime_com_0_79274784-253e-46ef-a7df-45c848b8582b_9cdc8b9e-e148-4bed-a62a-1374beae6eac\/ca345bfa-2c5d-487f-8aab-84e550eaf47e."},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0023","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.msard.2025.106878_bib0030","article-title":"Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis","volume":"7","author":"Piggott","year":"2021","journal-title":"Mult Scler J - Exp Transl Clin"},{"issue":"20","key":"10.1016\/j.msard.2025.106878_bib0007","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106878_bib0044","article-title":"Recommendations for essential medicines for multiple sclerosis in low-resource settings","author":"Saylor","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2025.106878_bib0031","volume":"1","author":"Sch\u00fcnemann","year":"2024"},{"issue":"22","key":"10.1016\/j.msard.2025.106878_bib0038","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.msard.2025.106878_bib0034","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Schunemann","year":"2014","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.msard.2025.106878_bib0040","unstructured":"Study Details | RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. | ClinicalTrials.Gov [Internet] [cited 2024 Aug 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05758831."},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0018","article-title":"Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study","volume":"6","author":"Tran","year":"2024","journal-title":"BMJ Neurol Open [Internet]"},{"issue":"9","key":"10.1016\/j.msard.2025.106878_bib0022","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.msard.2025.106878_bib0021","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of Rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.msard.2025.106878_bib0046","unstructured":"WHO Model List of Essential Medicines - 23rd list, 2023 [Internet] [cited 2024 Aug 2].. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02."},{"key":"10.1016\/j.msard.2025.106878_bib0037","unstructured":"World Bank Country and Lending Groups World Bank data Help Desk [Internet] [cited 2025 Jan 15]. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"10.1016\/j.msard.2025.106878_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2025.106878_bib0001","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Mult Scler J - Exp Transl Clin"},{"key":"10.1016\/j.msard.2025.106878_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102963","article-title":"Epidemiology of multiple sclerosis in Lebanon: a rising prevalence in the middle east","volume":"52","author":"Zeineddine","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106878_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104267","article-title":"Barriers to access multiple sclerosis disease-modifying therapies in Middle East and North Africa: a regional survey-based study","volume":"71","author":"Zeineddine","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.msard.2025.106878_bib0026","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2146\/ajhp120035","article-title":"Stability of stock and diluted rituximab","volume":"70","author":"Zhang","year":"2013","journal-title":"Am J Health Syst Pharm"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:28:58Z","timestamp":1781076538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S2211034825006200"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106878","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106878"}}